We enrolled 25 patients with extensive, steroid-refractory chronic graft-versus-host disease (cGVHD) in a prospective trial evaluating the efficacy of extracorporeal photophoresis (ECP) in both skin and visceral cGVHD. The median time from transplant to initiation of ECP was 790 days. ECP was administered for 2 consecutive days every 2 weeks in 17 patients and once a week in eight patients until best response or stable disease. The median duration of therapy was 9 months (range 3-24 months). In all, 20 patients had improvement in cutaneous GVHD and six had healing of oral ulcerations. Steroid sparing or discontinuation of immunosuppressive medications was possible in 80% of patients. Response rates were similar between patients receiving treatment weekly vs every 2 weeks and in patients commencing ECP less than vs greater than 18 months from transplant (70 vs 66%). When patients were stratified based on the Akpek prognostic score, there was no difference in overall response between the favorable (Akpek scoreo2.5) and unfavorable risk groups, but patients with progressive onset cGVHD tended to have a higher response than those with de novo onset. In summary, we report improvement in skin and/or visceral cGVHD in 71% overall and 61% of high-risk patients.
1
Factors associated with cGVHD include increased donor and recipient age, HLA-disparate and -unrelated donor transplants, prior acute GVHD and use of alloimmune female donors. Minor antigen mismatches cause donor T-cell activation against recipient tissues after contact with antigen-presenting cells. 2 While the etiology of cGVHD has not been fully elucidated, dysregulation of immune effector and suppression of normal natural killer (NK) cell populations has been demonstrated. 3 Clinical management of extensive cGVHD has been difficult after patients have failed to respond to steroids, cyclosporine, mycophenolate mofetil (MMF) and tacrolimus. 4 Ultraviolet A therapy (PUVA), while effective in alleviating the symptoms of chronic skin GVHD, has had no impact on visceral manifestations. [4] [5] [6] [7] Extracorporeal photopheresis (ECP) has been shown to be efficacious in the treatment of cutaneous T-cell lymphoma (CTCL), selected autoimmune disorders and solid organ allograft rejection. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] While the mechanism of action of ECP in autoimmune disorders is still not fully defined, it is believed that in CTCL patients, the combination of ultraviolet light and 8-methoxypsoralen induces apoptosis in a small subset of circulating clonal tumor or autoreactive T-lymphocytes, resulting in the stimulation of a cytotoxic T-cell response against the clone.
19, 20 A number of retrospective reports have demonstrated efficacy of ECP therapy in patients with skin and visceral manifestations of cGVHD, but little information is available regarding prognostic or biological variables predictive of response. 5, 6, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] In this prospective study, we analyzed response and prognostic variables in 25 steroid-refractory cGVHD patients treated with ECP on a twice-or once-weekly schedule.
Patients, materials and methods

Patients
In all, 25 patients with refractory cGVHD were enrolled on this prospective trial, including two patients under the age of 18 years. Results from the first 14 enrolled patients were previously presented in part. 22 All patients had undergone allogeneic transplantation for hematologic malignancy and did not have relapse of their underlying disease at the time of study enrollment. Patients were selected based on a body weight of at least 40 kg, ability to tolerate the ECP procedure and the presence of refractory cGVHD after treatment with steroids, cyclosporin A (CSA), tacrolimus and/or MMF. All patients had been steroid-refractory or steroid-intolerant prior to the institution of other immunosuppressive agents. At the time of study entry, patients had ongoing refractory skin and/or visceral cGVHD. GVHD grading was according to Sullivan et al. 39 The protocol received Institutional Review Board approval, and signed, informed consent was obtained from every patient before study entry.
ECP procedure
ECP was performed on an outpatient basis using the XTS photopheresis machine (Therakos Inc.) according to standard procedures in the manufacturer's guidelines. All patients received UVADEX injected directly into the recirculation bag of the ECP circuit after completion of the six cycles of buffy-coat collection just prior to photoactivation. The dose of UVADEX was based on the treatment volume collected during the plasma/buffy-coat collection process and was calculated using the following formula: treatment volume in ml Â 0.017 ¼ UVADEX (ml) added to the bag. ECP was administered for 2 consecutive days every 2 weeks to 17 patients and weekly to eight patients who lived a long distance from the treatment center.
Treatment monitoring
Response to therapy and assessment of skin and visceral cGVHD were performed monthly while on study. Doses of all immunosuppressive medications were documented at the beginning of ECP and during therapy. Corticosteroids were tapered based on documented clinical improvement in cGVHD. Then, MMF, CSA or tacrolimus were tapered as tolerated and discontinued if possible. Patients remained on study until progression of cGVHD or response plateau for at least 2 months while receiving ECP. Response in skin GVHD was measured as a 50% or greater improvement in area involved with rash. Changes in skin thickening were noted based on improved joint mobility or ability to pinch skin over sclerodermatous areas. Improvement in liver GVHD was determined based on a 50% or greater improvement in bilirubin (decrease of 2 mg/dl for patients with a baseline of 2-4 mg/dl; a decrease of X2 mg/dl in patients with a baseline of 4-8 mg/ or a 25% decrease for patients with a baseline X8 mg/dl). Gastrointestinal involvement was documented by rectal biopsy and improvement was determined based on decreased frequency of stools.
Statistical analysis
Univariate analysis was performed to determine whether there was a correlation between clinical parameters and response to ECP. These included donor status (related vs unrelated) and time from transplant to initiation of ECP (less than or greater than 18 months), type of GVHD (progressive onset vs de novo) and Akpek score. Categorical factors were compared using Cochran-Mantel-Haenszel statistics with P-values of p0.05 needed to be designated significant. Overall survival was calculated based on the Kaplan-Meier method.
Results
Demographics
All patients who presented with refractory, extensive cGVHD were evaluated for entry into the study. Of the 23 adult patients, the median age was 42 years (range 18-59 years). All patients had extensive cGVHD as described in Table 1 . All were refractory to multiple immunosuppressive medications . The median time from transplant to initiation of ECP was 790 days (range 242-2928 days). At study entry, patients were evaluated using Akpek's prognostic model for cGVHD. 40 In total, 17 patients had a score of 2.5 or greater, placing them into the highest risk group (Table 2) . ECP was administered until best response or progression for a median of 9 months (range 3-24 months).
Response to treatment
This was assessed monthly and was based on response in the skin as well as symptomatic assessment of visceral sites of involvement. Tapering of immunosuppressive agents during ECP was not considered a criterion for response. The overall response rate (response in at least one site of disease) was 64% (Table 3 ). In all, 20 patients had improvement in cutaneous GVHD including softening of sclerodermatous changes in six, and healing of skin ulcers in three. One of these was a 15-year-old male with severe sclerodermatous involvement of the trunk resulting in restrictive lung disease. The skin tightening softened significantly with ECP, with marked improvement in lung volumes on pulmonary function testing. Six of 13 patients with oral mucosal involvement experienced healing of the ulcerations while on ECP. Three out of six with joint involvement had increased flexibility of involved joints measured by the range of motion. One patient with lung involvement had a 50% improvement in DLCO and one with biopsy proven cGVHD of the gut had resolution of diarrhea. Three pediatric patients with keratoconjunctivitis sica had symptomatic improvement on ECP.
In all, 15 patients developed serious adverse events during therapy. Five had pneumonia, including one with cytomegalovirus and one associated with Norcardia. Cytomegalovirus-associated colitis, gastrointestinal bleeding associated with gastrointenstinal GVHD and urosepsis with subsequent renal failure from Tobramycin therapy occurred in one patient each. Two patients developed complications related to the indwelling venous catheter, one with staphylococcus epidermitis line sepsis and one with a deep venous thrombosis of the superior vena cava related to the line. One patient discontinued ECP due to recurrence of acute myelogenous leukemia.
The median survival of the study population was 51 months from day 0 of allogeneic transplantation. Of the 10 patients who died, the median number of cycles of ECP that they received was 5, whereas in the survivors it was 12. The median survival for responders vs nonresponders was 55 vs 39 months (P ¼ 0.3), as shown in Figure 1 .
Many responding patients had the doses of their immunosuppressive medications reduced while on ECP (Table 3 ). In this group of heavily pretreated patients, 10 were receiving three or more medications at the time of study entry. Although the protocol did not stipulate a precise algorithm for decreasing or stopping immunosuppression, corticosteroids were tapered first. In all, 11 patients had a decrease in corticosteroid dose while on ECP, 12 had a reduction or discontinuation of MMF and five reduction or discontinuation of tacrolimus. Four patients who had stable disease (no documented change in skin or visceral manifestations) had a reduction in immunosuppressive medications during ECP without evidence of disease flare.
When patient characteristics were examined and correlated with response, we found that response rates were similar (70 vs 66%) in patients who started ECP earlier after onset of cGVHD (18 months or less from the time of transplant) vs those who had more long-standing cGVHD and in patients with a matched unrelated donor (MUD) (40%) vs a matched related donor (MRD) (60%), as shown in Table 4 . While patients with progressive onset of cGVHD had a higher response rate (64%) compared to those with de novo onset (36%), the difference for this small number of patients was not statistically significant (P ¼ 0.42). When the Akpek prognostic score was calculated based on thrombocytopenia, de novo vs progressive onset of cGVHD, and limited vs extensive skin involvement, 17 of the 25 patients had a score of 2.5 or greater, Extracorporeal photopheresis in cGVHD FM Foss et al placing them into an unfavorable prognostic group. The response rate (58%) in this group, however, was similar to that in the favorable group (62%, P ¼ 0.86), which had an Akpek scoreo2.5.
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Discussion ECP was initially developed as a therapy for CTC by Edelson et al. 8 A number of studies have demonstrated response rates of 20-60% in patients with Sezary syndrome. 18, 41, 42 Later, studies reported efficacy of this treatment in autoimmune-mediated disorders, progressive systemic sclerosis, GVHD and allograft rejection. 30, [32] [33] [34] [35] [36] [37] Two recent studies reported results of ECP in 11 and 15 patients, respectively, who had failed first-and second-line therapies including corticosteroids and CSA. In one study, ECP was initiated late after the onset of cGVHD (median 510 days), while in another, it was initiated early (at a median of 178 days). 24, 26 In the group treated early, 12/15 patients had improvement in skin score, 11/11 in mucocutaneous disease, 7/10 in levels of hepatic enzymes and 5/6 in ocular symptoms. In the group treated late after onset of Type of onset of GVHD Progressive:
Correlations were calculated based on the Cochran-Mantel-Haenszel method.
cGVHD, there was still a skin response in 10/10 patients, but only 2/4 with oral and 1/5 with liver involvement had demonstrated improvement. A retrospective series of 32 patients with steroidrefractory or steroid-dependent chronic GVHD by Apisarnthanarax et al 38 describes a similar population as were treated in our study. The authors report results on 28 patients with extensive cutaneous cGVHD; 72% had visceral involvement but responses were scored based only on cutaneous disease. The overall response rate was similar to our series at 56% (seven CR, 11 PR), with 64% of patients experiencing a steroid-sparing effect from ECP. Some of the patients in this study received more intensive therapy than in our study, with a median of 36 ECP sessions over a median of 5.3 months, and with 10 patients receiving 10 or more treatments per month. The effect of dose intensity in that study was unclear since the response rate in the group receiving 10 or more treatments per month was similar to that of patients receiving ECP every 2 weeks; likewise in our study, there was no difference between weekly and two-weekly scheduling of ECP and response rate.
Steroid sparing or reduction of other medications has been identified as an important beneficial effect of ECP therapy in patients with cGVHD who suffer substantial morbidity and mortality related to immunosuppression. In all, 11 patients (44%) in our series had at least one immunosuppressive medication discontinued after initiation of ECP, and 13 had a reduction of corticosteroids. Apisarnthanarax et al 38 report a steroid-sparing effect in 64% of patient after ECP, including several who had no measurable response in skin GVHD. The ability to reduce immunosuppressive medications may account, in part, for the improved survival observed in the responders in both of these series.
As most reports of ECP in cGVHD have been retrospective, the predictors of response have not been well defined. Donor status (MRD vs MUD) appears not to correlate with response to ECP but does appear to be associated with a higher mortality rate in both our study and in that of Apisarnthanarax et al. 38 The timing of initiation of ECP, early in the course of treatment for cGVHD or later (41 year from onset), was not a significant predictor of response, in contrast to Child et al 24 who noted a higher response rate in skin GVHD in patients who started ECP earlier than 1 year after onset of cGVHD. The median time from transplant to ECP was similar in our series and that of Apisarnthanarax et al 38 (24, 26 months, respectively), and median time from onset of cGVHD and ECP was 17 months in the responders in both studies. As it is difficult to assess risk groups among the patients in these series, it is impossible to conclude that the efficacy of ECP is lower in patients with long-standing chronic skin and visceral GVHD. Both our study and that of Apisarnthanarax et al reported response rates of 50 and 80%, respectively, in patients treated with ECP 3 or more years after onset of cGVHD, supporting the use of ECP in this setting.
Severity, extent and type of cGVHD may be an additional factor associated with response to ECP. The Akpek scoring system had defined prognostic groups based on progressive vs de novo onset of cGVHD, degree of skin involvement and thrombocytopenia, and has demonstrated that patients with a prognostic score of at least 2.5 have an inferior outcome, with a disease-specific survival of 34%. 40 In our study, overall survival in the high-risk group was similar to that reported by Akpek et al; moreover, there was no statistically significant difference in overall response rate between the low-and high-risk groups. In the series by Apisarnthanarax et al, patients were not grouped based on the Akpek criteria, but patients with progressive onset of cGVHD had an inferior outcome (response rate 46%) compared to those with de novo onset (64%), similar to the results reported here, suggesting a trend toward an improved response rate in this group of patients.
The mechanism of action of ECP in cGVHD is not fully understood. It has been proposed that ECP modulates host effector cells, including CD8 þ T-lymphocytes, NK cells and circulating antigen-presenting cells, leading to an attenuation of host antigen-presenting activity, thereby leading to the development of tolerance. 3, 22 Evidence supporting the role of intact host dendritic cells in GVHD has been derived from studies by Shlomchik et al 43 who demonstrated in a murine GVHD model that the initial targets for CD8 þ T cells in GVHD were restricted to proteins expressed by residual host antigen-presenting dendritic cells. 43 The use of ECP as part of a transplant conditioning regimen has been associated with a lower incidence of aGVHD and cGVHD, possibly related to early engraftment of donor dendritic cells. 44 The nature of dendritic cell reconstitution after various conditioning regimens used in allogeneic bone marrow transplantation is currently being defined and may well be predictive of response to therapies for GVHD, including ECP.
In summary, our results confirm those reported in a number of retrospective studies and demonstrate that ECP is an active therapy for patients with cGVHD irrespective of the type of transplant (MUD vs MRD), duration of cGVHD or Akpek risk stratification. There may be a trend toward a higher response rate in patients with progressive, rather than de novo onset, of cGVHD. Our results are in concordance with those of Apisarnthanarax et al 38 in that there appears to be no association between dose intensity (number of ECP treatments per month) and clinical response. As the small numbers of patients in these and other published Phase II trials, it is difficult to accurately determine predictors of response to ECP. A current multinational randomized study is underway, which will further examine the benefit of ECP in these patients.
